Lipid-based systemic delivery of siRNA by Tseng, Yu Cheng et al.
Lipid-based systemic delivery of siRNA
Yu-Cheng Tseng1,3, Subho Mozumdar1,2,3, and Leaf Huang1
1Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel
Hill, NC 27599, USA
2Department of Chemistry, University of Delhi, Delhi 110007, India
Abstract
RNAi technology has brought a new category of treatments for various diseases including genetic
diseases, viral diseases, and cancer. Despite the great versatility of RNAi that can down regulate
almost any protein in the cells, the delicate and precise machinery used for silencing is the same.
The major challenge indeed for RNAi-based therapy is the delivery system. In this review, we
start with the uniqueness and mechanism of RNAi machinery and the utility of RNAi in
therapeutics. Then we discuss the challenges in systemic siRNA delivery by dividing them into
two categories--kinetic and physical barriers. At the end, we discuss different strategies to
overcome these barriers, especially focusing on the step of endosome escape. Toxicity issues and
current successful examples for lipid-based delivery are also included in the review.
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2. Introduction
2.1 Discovery and uniqueness of RNAi
Post-transcriptional gene silencing by RNA interference, popularly known as RNAi, is a
phenomenon that is exploited by cells to conduct gene regulation. This was first observed in
plants by Napoli et al. [1]. The mechanism of gene suppression was finally established by
Fire et al. [2] with the demonstration that when short stretches of 23mer to 25mer nucleotide
sequence of double stranded RNA molecules were injected in C .elegans, complete
degradation occurred of mRNA that was complementary to one of the strands of the injected
double stranded RNA. This type of gene silencing, though initially shown to be a transient
phenomenon, was later shown to be of a more stable type when short hairpin RNA
containing the complementary feature of the double stranded RNA could be expressed in
organisms as varied as C. elegans, Drosophila and plants [3–5]. The initially used double
stranded RNA is now called siRNA and the later synthesized single stranded short hairpin
RNA are called shRNA.
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The uniqueness and impact of this discovery can be gauged from the fact that the initial
discovery was done in the 1990s, the mechanism established by Fire et al. [2] in 1998,
“breakthrough of the year” declared by the Science magazine in 2002 and the Nobel Prize
for Medicine or Physiology awarded to its discoverers, Andrew Fire and Craig Mello, in
2006. What distinguishes this mode of gene silencing from the already established anti-sense
mode of gene silencing is that though in both the methods the sequence complementarity
feature on the mRNA is utilized for target recognition, the RNAi mechanism has a catalytic
component incorporated into it, in the sense that a single siRNA/ shRNA molecule can
silence or destroy thousands of copies of mRNA molecules. This machinery is extremely
efficient as compared to the anti-sense technology, where a single anti-sense nucleic acid
molecule can bind to and thereby silence only a single mRNA molecule.
2.2 Mechanism of action
In mammalian cell, siRNA is generated by the cleavage of larger double-stranded RNA
(dsRNA) precursors by the RNAse III endonuclease Dicer [6]. Dicer is complexed with the
TAR-RNA binding protein (TRBP) and hands off the siRNA to the RNA-induced silencing
complex (RISC). RISC contains the protein that carries out the silencing activity by cleaving
the target mRNA molecule between bases 10 and 11 relative to the 5’ end of the antisense
siRNA strand. In the core of RISC lies the Argonaute (Ago) family members and in humans,
Ago-2 carries out the catalytic cleavage activity [7, 8]. It has been observed that although the
siRNA transferred to RISC are double stranded, Ago-2 cleaves and releases the “passenger”
strand, leading to an activated form of RISC that contains a single-stranded “guide” RNA
molecule. It is this guide RNA molecule that confers the specificity to the RISC and helps it
in target recognition by intermolecular base pairing [9]. The selectivity of strand loading
into RISC is governed by differential thermodynamic stabilities of the end of the siRNA [10,
11]. The less thermodynamically stable end is chosen for unwinding of the 5’ end of the
guide strand and this binds to Ago-2. Ago-2 is composed of three domains: PAZ, MID, and
PIWI domains. The function of PAZ and MID domains are docking and anchoring the RNA.
PIWI domain is the one with slicer activity [12]. Messenger RNA molecule that displays
perfect or near-perfect complementarity to the guide RNA are recognized and cleaved by
Ago-2. Partial complementarity between a siRNA and target mRNA may in some cases
repress translation or destabilize the transcripts if the binding mimics microRNA (miRNA)
interactions with target sites. miRNA is actually the endogenous substrates for the RNAi
machinery. It is initially expressed as long primary transcript (pre-miRNA) which is
processed within the nucleus into 60–70bp hairpin by the microprocessor complex that
consists of Drosha-DGCR8 [13, 14]. Finally, the loop is removed by further processing in
the cytoplasm by the RNAse III Dicer and only one of the two strands is loaded into RISC in
the cytoplasm. The mature miRNA can share only partial complementarity with sequences
in the 3’UTR of target mRNA. The primary mechanism of action of miRNA is translation
repression, although this can be accompanied by message degradation [15].
3. Utility of RNAi in therapeutics
It is possible to exploit this native gene silencing pathway for regulating gene(s) of choice.
There are a number of methods for doing so. If a siRNA effector molecule with one strand
having a complementarity match with a target nucleotide sequence is delivered into a cell, it
can activate RISC directly and can result in specific silencing of the targeted mRNA. It is
the reason why the procedure has become the method of choice for silencing specific gene
expression in mammalian cells. Control of disease-associated genes can therefore make
RNAi an attractive choice for future therapeutics. It can be envisaged that every human
disease is caused by activity from one or a few genes and some of these genes should be
amenable for RNAi intervention. The list of such disease includes cancer, cardiovascular
and autoimmune disorders, dominant genetic disorders and viral infections. Moreover, the
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fact that miRNA can function both as tumor repressor and oncogene, endogenous miRNA
can also become therapeutic target [16]. Although RNAi therapy is of great potentials, the
technology still has one major limitation--it can only achieve “lost of function” therapy. If
the disease is caused by loss function of genes, the strategy should be introducing gene
expression by virus or plasmid. Thus, the traditional gene therapy approach should be
complementary to the RNAi approach.
In addition to the activities in utilizing the promise of RNAi technology in creating gene
knockouts by stable transfection of short hairpin RNA (shRNA) [17, 18] or cre-lox mediated
knockdown of genes in transgenics [19], there has been an increasing amount of efforts in
harnessing this powerful technology for therapeutic purposes. But in order to become a
therapeutic modality, certain issues of drug development have to be addressed. First of all,
the drug should be manufactured at reasonable cost and be suitable for administration in a
safe and convenient manner. Second, it must be stable and accumulate to an effective level
in the target cell. Third, it must be restricted in its effect on or within the target cell. Finally,
it must not pose any toxicity to other cells. Keeping these fundamental issues in mind, some
of the areas where siRNA can be used as a potent therapeutic molecule are as follows:
3.1 Genetic Diseases
There is a big promise that siRNA can be successfully used to treat a large number of
genetic diseases. Preliminary studies have revealed that single nucleotide polymorphism in
mutant allele transcripts can be used as effective targets for RNAi [20, 21]. One of the
challenging targets for siRNA based therapeutics is the disease causing polyglutamine
proteins encoded by the CAG repeat containing transcripts. Such repeats are found in
several neurological diseases. But the problem is that the repeats are also found in many
normal transcripts as well. As a result, they are difficult to be selectively targeted by siRNA.
Alternatively, single nucleotide polymorphisms (SNP) are very often found in mutant allele
transcripts and represent potential selective targets. The challenge is therefore to find a
siRNA/SNP combination that is highly selective. This has been accomplished by systematic
analyses of siRNA in which the polymorphic nucleotide is complementary to the mid region
of the siRNA. In some cases, the siRNA directs selective degradation of only the mutant
transcripts, leaving the wild type transcripts intact despite having only a single mismatch
with the wild type sequence [20, 21]. An additional application of siRNA targeting a SNP
has been reported in the studies of amyotrophic lateral sclerosis (ALS) [22]. This disease is
caused by mutations in the Cu, Zn superoxide dismutase (SOD1) gene. Recently, siRNA has
been systematically tested for their ability to discriminate wild type from mutant alleles for
the SOD1 and the huntingtin (HTT) gene [23]. These studies have supported the notion that
single nucleotide polymorphisms may indeed suffice to make mutant specific siRNA if
mismatches are placed rationally within their sequence. Particular purine-purine mismatches
at positions 10 and 16 relative to the 5’ end of the guide strand can provide selectivity. Since
the wild type SOD1 performs important functions it is important to selectively eliminate the
expression of only the mutant allelic transcript. Based on the above studies, it has been
possible to achieve selective degradation of a mutant allele encoding SOD1, thereby
providing a potential therapeutic application for the treatment of ALS. Furthermore, since
siRNA and viral vectors encapsulating siRNA can be technically delivered to affected
regions of the brain [24], the promise of clinical use of RNAi for treatment of degenerative,
neurological diseases is expected to become a reality soon.
3.2 Viral Diseases
Initial application of the RNAi technology had been directed in the treatment of hepatitis B
[25]. A significant knockdown (99%) of the hepatitis B virus (HBV) core antigens could be
achieved in liver hepatocytes by using shRNA directed against them.
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Hepatitis C virus (HCV) infects an estimated 3% of the world’s population and is a major
cause of chronic liver disease, leading to the development of liver cirrhosis and
hepatocellular carcinoma. The HCV genome is a positive-strand RNA molecule with a
single open reading frame encoding a polyprotein that is processed post-translationally to
produce at least ten proteins. The efficacy of siRNA mediated inhibition of virus replication
has been studied in a number of replicon systems [26–28]. One of the encouraging results
has been the one where siRNA has been targeted against the internal ribosomal entry site
(IRES) and against non-structural protein NS3 and NS5b [27]. Similarly, anti-HCV siRNA
has been shown to cure Huh-7.5 cells bearing persistently replicating HCV replicons [26]. In
another study, both synthetic and Pol III promoter expressed anti-HCV siRNAs have been
shown to direct efficient cleavage of HCV sequences in a HCV-luciferase fusion construct
in vivo in mouse hepatocytes [29]. In a different in vivo study, siRNA has been used to treat
fulminant hepatitis induced by an agonistic Fas-specific antibody in mice. Delivery of anti-
Fas siRNA resulted in a survival rate of 82% in the treated mice after 10 days of
observation, whereas the un-treated control mice died within 3 days [30].
HIV is another infectious agent that can be targeted by RNAi. This may be because of the
fact that the life cycle of HIV is well understood together with its pattern of gene expression.
Synthetic and expressed siRNAs have been used to target a number of early and late HIV-
encoded RNAs and these include the TAR element [31], tat [32–34], rev [32, 34], gag [35,
36], env [36], vif [31], nef [31] and reverse transcriptase [34]. Cellular cofactors, such as
NF-kb [34], the HIV receptor CD4 [35] and co-receptors CXCR4 and CCR5 [37] have also
been successfully down-regulated by RNAi resulting in an inhibition of HIV replication.
Moreover, inhibition of HIV replication has been achieved in numerous human cell lines
and primary cells including T lymphocytes and hematopoietic stem cell derived
macrophages [32, 34, 37–40].
Despite the success of in vitro RNAi-mediated inhibition of HIV-1, for future clinical
applications, targeting the virus directly represents a substantial challenge since the high
viral mutation rate will certainly lead to escape of mutants [41]. RNAi-mediated down-
regulation of cellular co-factors required for HIV infection is an attractive alternative or
complementary approach. One such target that holds particular promise is the macrophage-
tropic chemokine (C-C motif) receptor 5 (CCR5) [42] that HIV uses as the most important
co-receptor during the infection. CCR5 is non-essential for normal immune function.
Individuals homozygous for a 32 bp deletion in this gene show resistance to HIV infection
and individuals who are heterozygous for this deletion have delayed progression to AIDS
[43, 44]. Based on this, Pol III expressed anti-CCR5 shRNA have been used to knocking off
the expression of the gene in human lymphocytes [45]. Down-regulation of CCR5 resulted
in a somewhat modest, but nevertheless significant 3 to 7 fold reduction in viral infectivity
relative to controls. Despite this down-regulation, the anti-CCR5 shRNA treated cells were
still susceptible to infection by T-tropic CXCR4 utilizing virus. This emphasizes the need to
combine several shRNA against co-receptors and the virus in order to achieve a potent
inhibition of HIV-1. Clinical trials have been undertaken where T lymphocytes from HIV
infected individuals were utilized and transduced ex vivo with a lentiviral vector that
encoded an anti-HIV antisense RNA. The transduced cells were subsequently expanded and
reinfused into patients [46, 47]. This type of therapeutic approach is certainly applicable to
vectors harboring genes that encode siRNA. A different approach is to transduce isolated
hematopoietic progenitor or stem cells with the vector. This approach has the advantage that
all the hematopoietic cells capable of being infected by the virus are derived from a multi-
potent stem cell that can be transduced with an appropriate viral vector. Hematopoietic stem
cells can be mobilized from the patients and transduced ex vivo prior to reinfusion.
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The use of RNAi for cancer therapeutics has the potentiality of revolutionizing the treatment
of this devastating disease. The challenges for cancer are not dissimilar to those faced by
other diseases. In most cases, mouse xenograft models have been used in studying the effect
of the RNAi treatments [48]. In one case, shRNA targeting Hec1 has been delivered to show
efficacy for treating adenocarcinoma-induced tumor growth [49]. Generally, RNAi mediated
cancer therapies include: 1. Inhibit angiogenesis via inhibiting VEGF-signaling [50–55]; 2.
Inhibit tumor survival and induce apoptosis [56] via inhibiting Wnt pathway [57, 58], NF-
κB pathway [59, 60], EGFR [61], Her-2/ neu [62], telomerase [63, 64], MDM2 and p53 [65,
66], or Bcl-2 [67]; 3. Enhance radio- or chemo-sensitivity by inhibit MDR1 [63, 64].
Combination siRNA therapy that inhibits multiple pathways shows great anti-tumor effect
and could be a novel approach for anti-cancer therapy [68, 69].
4. Delivery of RNAi
4.1 Challenges in delivery
For a successful siRNA delivery, the final destination is the cytoplasm of the target cells.
Although this is one barrier (the nucleus membrane) less than delivering plasmid, it still
remains a great challenge. The first concern is the stability of siRNA itself. Naked siRNA is
prone to degradation and has a half life less than five minutes in plasma [70]. Their
relatively small size also leads to rapid clearance by kidney filtration after systemic
injection. Together with the negatively charged nature of siRNA that prevent it from having
association with cell membrane, it’s unlikely to simply use siRNA itself as a drug
formulation. When formulate into a delivery system, the stability of the delivery formulation
is another issue and it also needs to escape from the non-specific uptake by the
reticuloendothelial system (RES), especially the Kupffer cells in the liver and the
macrophages in the spleen. Even if the siRNA stays in the blood circulation long enough,
the siRNA formulation has to extravasate and gain access to the target tissue if the target is
not blood cells or blood vessel cells. All the above is considered as the “kinetic barriers”
which prevent the siRNA formulation from having “the access to the target cells”. The other
category of barriers, i.e., the “physical barrier”, is the hurdles that impede “the access to
the cytoplasm”. First, the siRNA needs to get across the cell membrane. The most
commonly used delivery strategy for macromolecules including siRNA is to take advantage
of the receptor-mediated endocytosis. Second, endocytosed siRNA will need to escape the
endosome or caveosome to reach the cellular cytoplasm where the RISC locates.
In the case of expressing shRNA in the target cells by delivering a plasmid, plasmid vectors
[71–75] or viral vectors [76] are commonly used. Plasmid vectors have been successfully
used in mammalian cells in vitro by simple transfection. Plasmid vectors need to cross the
nuclear membrane for transcription. This is not a serious problem for cells actively growing
in culture, because the nuclear membrane disappears during mitosis. For primary cells that
are usually not actively dividing, delivering siRNA is more favorable than the plasmid. Viral
vectors that can transduce non-dividing cells [77, 78] are usually used for introducing
shRNA in primary cells. Lentiviral and other retroviral vectors have been used extensively
for stable expression of shRNA due to their ability to insert into the host genome. Adeno
associated virus is non-pathogenic and can also achieve long term gene expression.
Adenoviruses is known for its robust expression and herpes simplex virus is useful for its
neuron-tropism [79]. However, immunogenicity and other safety issues are still great
concerns of using viral vectors in human. On the other hand, molecular encapsulation of
siRNA by non-viral vectors such as liposomes and other nanoparticles are preferred
approach because of their low immunogenicity and high biocompatibility.
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4.2 Strategies in lipid-based systemic siRNA delivery
There are many different types of non-viral delivery strategies. They include physical
methods, such as hydrodynamic injection [80–82], particle bombardment [83] and
electroporation [84–86], and chemical methods. Polymer, including proteins and peptides,
mediated delivery of siRNA has been attempted by many investigators [87–90]. But this
review will concentrate on the lipid-based vectors. Furthermore, only systematic deliveries
will be discussed; local or topical deliveries will not be included. The following discussion
is designed to address the two major barriers mentioned above, mainly using solid tumor as
examples.
4.2.1 Kinetic barriers—Since safety and efficient delivery of siRNA is a necessary pre-
condition for the delivery of a potential siRNA based therapy, the stability of the siRNA
molecule becomes a major lingering issue [91]. In this regards, the in vivo stability of the
siRNA molecule has been achieved by chemically modifying the basic RNA structure, and
several methodologies are currently available for changing the backbone of the RNA
molecule. It can not only lead to enhanced in vivo stability but also reduce in the dose of
siRNA that is typically required for achieving a desired therapeutic effect. The strategies
involve substituting the 2’-OH group on the ribose ring with –F, -O-Me, or simple –H
groups to improve the stability of siRNA [92]. It has been observed that this type of
selective substitution of the 2’-OH group does not reduce the efficiency of the RNAi effect
[93]. Yet another modification is a phosphorothioate modification of the RNA backbone
[70]. It has also been shown that linking a cholesterol molecule to the 3’ end of the sense
strand of a siRNA molecule can suppress the siRNA degradation in a cell culture system
[29, 80, 94]. This type of chemical modification has also been used widely on aptamer
research. In fact, the most simple siRNA delivery design is the one that simply links siRNA
with a RNA aptamer targeting prostate specific membrane antigen (PSMA) [95]. But the in
vivo anti-cancer effect was only done with intra-tumor injection. Until now, no successful
systemic delivery using the aptamer-siRNA chimera has been reported. It’s also worthy to
note that in one study, simultaneous application of siRNA and aptamers against the
transcription factor NF-κB could produce 90% knockdown, whereas either modality alone
could only produce 60% inhibition [96]. Since aptamers bind and inhibit signaling protein in
a different mechanism from that of RNAi, it provides another strategy for combination
therapy with RNAi.
Cationic lipid formulations such as Lipofectamine 2000 [97, 98] or cardiolipin analogs [99,
100] have been widely used for in vitro plasmid DNA or siRNA delivery. By charge
complementarities, negatively charged nucleic acids and positively charged lipids
spontaneously form nanoparticles (called lipoplex) of 50 nm to 200 nm in diameter
[101-103]. With optimal N/P (nitrogen to phosphate, or +/−) ratio (usually around 2 or 3),
the complex has an overall positively charged surface and thus favors their interaction with
cell membrane. Lipid-mediated siRNA transfection is at least 1000 fold more efficient than
that of naked siRNA [98].
Though the information on the bio-distribution of the complex of siRNA with cationic
liposomes is rather scarce [104–106], it depends on the colloidal properties of the complex
as well as their interaction with blood components. Surface charge of the complex plays an
important role in determining the final destination of the complex. Complexes with a strong
anionic charge are usually absorbed by scavenger cells, resulting in a rapid elimination of
the injected dose from the blood. A strong positive charge can also create problems. For
example, following intravenous administration in mice, 60% of the dose of plasmid DNA
delivered as a complex with cationic liposome accumulated in the liver. However, the level
of transgene expression per microgram of DNA taken up in the tissue was a 1000-fold lower
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in the liver than in the lung. The decreased transgene expression in the liver may be due to
the rapid degradation of DNA following phagocytosis of the lipoplex by the Kupffer cells
[107]. This phenomenon falls into the same category of delivery problem for other colloidal
carriers, i.e. strong uptake by the reticuloendothelial system (RES), which include the
Kupffer cells in the liver [108]. The reason why unprotected lipoplex is prone to RES uptake
is because opsonins such as IgM, IgG, fibronectins, or complement C3 attaching to the bare
surface of lipoplex can attract phagocytic cells. One way to deal with this problem is to use
stealth liposome strategy with surface grafted carbohydrate or polyethylene glycol (PEG) for
protection and shielding the surface charge [109]. PEGylation of liposomes can increase the
circulation half life of the i.v. injected liposomes to 6–10h in mice and to about 40h in
human [110].
In a recent study, lipid-mediated delivery of a siRNA against apolipoprotein B (apoB) has
been used to target apoB mRNA in the liver. Administration of the apoB-specific siRNA
without a formulation or chemical conjugation showed no in vivo silencing activity even at
doses higher than 50 mg/kg [92]. However, more than 80% silencing of apoB mRNA and
apoB-100 protein could be achieved with a single 1 mg/kg dose of lipid-formulated siRNA
in a non-human primate [104]. The lipid formulation in this case contained the lipids 3-N-
[(ω-methoxypoly(ethylene glycol)2000) carbamoyl]-1,2-dimyristoyloxy-propylamine (PEG-
C-DMA), 1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane, (DLinDMA), 1,2-distearoyl-sn-
glycerol-3-phosphocholine (DSPC) and cholesterol, in a 2:40:10:48 molar ratio. A major
fraction of the siRNA delivered intravenously using this vector accumulated in the liver,
followed by spleen and small intestine. How much of the liver uptake was due to the
hepatocytes and how much due to the Kupffer cells was not known.
For delivering siRNA to solid tumor cells, it is important to review the work of Matsumura
and Maeda [111]. They discovered that macromolecules and colloidal nanoparticles could
accumulate in the solid tumor due to the leaky neovasculature of the tumor [112–115].
Accumulation of the Stealth liposomes [61] and other PEGylated colloidal systems [116,
117] in the tumor due to the so called Enhanced Permeability and Retention (EPR) effect is
also contributed by the fact that tumor lacks the lymphatic drainage like the normal tissues
[111, 118, 119]. It must be remembered that the degree of leakiness of the neovasculature
varies among different tumors [120]. Although the EPR effect has been demonstrated in
human [121–124], not all human tumors are equally leaky. For tumors with a not-so-leaky
neovasculature, nanoparticles with small size, e.g. less than 30 nm in diameter would be
desirable. Unfortunately, most of the self-assembled nanoparticles, lipid-based or polymer-
based, are larger than this size. Formulations with a small particle size may penetrate the
liver fenestrae and promote the uptake by the hepatocytes [125]. To provide improved
capacity and protection to siRNA, advanced core/shell lipid–based nanoparticles
(lipopolyplex) have been designed. The core consists of DNA (with or without siRNA)
condensed by a polycation by polyelectrolyte coacervation. The first such example was the
LPD (liposome-polycation-DNA) nanoparticles designed in our lab in the mid 90s [126]. To
deliver siRNA, we have used FDA approved protamine, a cationic polypeptide, to condense
siRNA with the help of the high molecular weight calf thymus DNA. The self-assembled
LPD nanoparticles were further modified by post-inserting a PEG-phospholipid conjugate
for surface protection [127]. Taking advantage of the EPR effect, the PEGylated LPD
nanoparticles can accumulate a high dose (60–80% injected dose per g of tissue) in the H460
lung cancer xenograft model [61]. Such very high tumor accumulation was not ligand
dependent, because particles with or without a targeting ligand, anisamide in this case [128],
the tumor uptake of the encapsulated siRNA was about the same [61]. However, due to the
presence of the sigma receptor on the H460 tumor cells, nanoparticles with anisamide were
internalized by the tumor cells. Nanoparticles without a targeting ligand stayed outside the
cells and accumulated in the interstitial fluid space in the tumor. siRNA delivered
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intracellularly by the anisamide targeted LPD nanoparticles almost completely silenced the
target gene after three daily injections [61]. Although the result is already promising,
confocal microscopy of tumor sections revealed that most of the fluorescently labeled
siRNA were still retained in the endosomes in the tumor cells and were thus not bio-
available [61]. Gene silencing could be accomplished by injecting a lower dose if the
formulation can efficiently release the encapsulated siRNA from the endosomes to the
cytoplasm. This subject is discussed in greater detail in the following section. In a similar
approach, a plasmid DNA encoding a short hairpin RNA (shRNA) condensed by poly-L-
lysine (PLL) into a Multifunctional Envelope type Nano Device (MEND) has been
developed by the Harashima group [129]. This system produced 96% inhibition of the
marker luciferase gene expression in the target cells.
It is important to mention that the LPD formulation contained 10 mol % surface grafted
PEG-phospholipid conjugate [61]. It is known that lipid bilayer can maximally tolerate only
about 5–6 mol % of PEGylation. This is due to the detergent-like activity of the PEG-
phospholipid conjugate which lyses liposomes at high concentrations. The LPD formulation
could be modified with a high amount of the conjugate because the lipid bilayer on the
surface of the LPD is stabilized by charge-charge interaction with the negatively charged
core. The high degree of PEGylation is probably the reason why the formulation is not taken
up by the liver and spleen to a significant degree [61]. The injected dose could then
extravasate into the tumor via the leaky neovasculature, i.e. the EPR effect.
4.2.2 Physical barriers—After a siRNA formulation gains access to the target cells, the
next step is to cross the cell membrane and enter into their action site—cytoplasm. Different
ligands such as cell penetrating peptides, proteins, antibodies (including Fab, scFv, etc.),
aptamers, and small molecular weight ligands have been used for binding and triggering
endocytosis. But only being endocytosed is not sufficient. In fact, the most challenging part
in siRNA delivery field now is how to get the siRNA out of the endosomes intactly. This
requires both endosome escape and sufficient de-assembling of the formulation. Fig. 1
shows the overall endosome escape mechanisms for lipid mediated siRNA delivery. The
details will be discussed below.
5. Endosome escape
5.1 Ion-pair formation (fusogenic property of liposomes & inverted hexagonal phase)
The mechanism by which cationic lipoplex triggers endosome release has been proposed by
Xu & Szoka [130]. After endocytosis, cationic lipids form ion pairs with the anionic lipids in
the endosome membrane and thus destabilize the endosomal membrane by excluding the
surface bound water (Fig.2) [130]. Electrostatic interaction between cationic lipid and
anionic lipid could further promote the formation of the inverted hexagonal (HII) phase as
purposed by Cullis et al [131]. Lipids with small and/or less hydrophilic head group and
bulky acyl or alkyl chains favor HII phase formation. Thus, cationic lipid with a C18:2 alkyl
chains showed higher delivery efficiency than the one with C18:1 chains [131]. DOTAP,
containing two C18:1 acyl chains, is a commonly used cationic lipid for transfection.
DSTAP, a close analog of DOTAP but with two C18:0 chains, is not. HII phase is an
intermediate structure when two lipid bilayers fuse with each other [132, 133]. In the
process of fusion, both bilayers are destabilized. Thus, the ion-pair formation between the
cationic lipids in the lipoplex and the anionic lipids in the endosome membrane not only
destabilizes the endosome membrane, but also promote the de-assembly of the lipoplex. Ion-
pair formation requires close contact of the lipids with opposite charges. PEGylation of
liposomes or LPD may significantly reduce the interactions between the cationic lipids and
the endosomal lipids due to steric hindrance. Since PEGylation of the vector is often
required to overcome the kinetic barriers as discussed above, this is a dilemma in the
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delivery of nucleic acid therapeutics. Tunable stealth liposomes [134], cleavable PEG-lipid
linker [135], or acid labile PEG molecule design could be the answers to this problem.
Besides cationic lipids, other protein transduction domain such as the famous HIV-1 Tat,
Drosophila Antennapedia transcription factor, herpes simplex virus type-1 VP22
transcription factor, or even just simple oligo-arginine (R8, R9) peptides also show the ion-
pair effect. It is interesting to note that many protein transduction domains contain arginine,
and not lysine. For example, oligo-arginine, but not oligo-lysine, shows a membrane
penetration activity [136]. Sakai & Matile [137] showed that the presence of multiple
guanidinium cations is important to their ion-pair formation in endosome that leads to
efficient endosome escape. The reason why oligo-lysine, which also has one positive charge
on each amino acid residue, does not work as well as oligo-arginine is a very interesting
question. Sakai & Matile proposed that this is because a guanidinium cation contains a
delocalized positive charge that can interaction with an anionic group which also contains a
delocalized negative charge. It is interesting to note that naturally occurring anionic groups
in biological molecules, including phosphate, carboxyl and sulfate, all contain the
delocalized negative charge. Fig. 3 demonstrates the ion-pair formation between the
delocalized positive charge of arginine and the delocalized negative charge of the phosphate
group. Please note that in additional to the charge-charge interaction, H-bondings are also
involved in the ion-pair. Note that the natural DNA condensing molecule in the sperm, i.e.,
protamine, is a polypeptide containing many arginines.
5.2 Proton sponge effect
Unlike lipoplex that relies on the fusogenic property of the lipid bilayer to mediate
endosomal escape, polymeric carriers such as polyethyleneimine (PEI) [138–141] are
supposed to use the so-called “proton sponge” effect to enhance endosomal release of the
endocytosed polyplex [142–145]. According to this mechanism, the unprotonated 1°–, 2°-
and 3°-amines in a polymer will show different pKa values due to crowding of the amines
and will confer a buffering effect over a wide range of pH. The buffering may protect the
siRNA from degradation in the endosomal compartment during the maturation of the early
endosomes to late endosomes and their subsequent fusion with the lysosomes. The buffering
property allows the polycation polyethyleneimine (PEI) to escape from the endosome. This
is because at the typically lower pH of the endosomes, the buffering capacity of PEI causes
an influx of protons, chloride ions and water into the endosomes, which eventually leads to
swelling and burst the endosome due to increased osmotic pressure. PEI is not the only
polymer has this buffering property, polymers containing crowded histidines (imidazoles) or
morpholinos also show the same effect [146]. In fact, the problem of PEI is its high cell
toxicity (especially the high MW PEI [141, 143, 147, 148]), although the purified PEI
polyplex show reduced toxicity and could be useful in vivo [149].
Although Verkman et al. did a beautiful piece of work showing chloride accumulation in the
endosomes containing the internalized polyplex and chloride release after osmotic swelling
[145], they did not provide direct evidence showing that the polyplex itself was released to
the cytoplasm. In fact, the protonation of the 2°- and 3°-amines in PEI may lead to even
stronger association with the bound DNA or siRNA and make it more difficult to de-
assemble. Boeckle et al. showed that the presence of free unbound PEI 4h after transfect
with purified polyplex can increase gene expression, probably by helping polyplex release
form the endosomes [150]. Thus, free PEI may form ion pair with negatively charged
endosome lipids and destabilize endosome membrane by excluding the surface water just
like cationic lipids as discussed above. If so, we predict that free oligo-arginine would
perform a better job than free PEI for reasons mentioned above. It is likely that proton
sponge effect itself might not be sufficient for endosome escape of the endocytosed DNA or
siRNA. Ion-pair formation may play a more important role in this case.
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The siRNA complex must de-assemble sufficiently in the endosome or in the cytoplasm so
that the released siRNA could access the RISC complex for gene silencing. The requirement
is the same in any other lipid- or polymer-based DNA/siRNA condensing formulation. If the
complex or condensed core is still bind tightly in the endosome, the size of the complex may
be too large for the membrane holes that generated during the endosome rupture and will not
escape. Strategies like enzyme active linker, acid labile cross-linkers [151], pH-sensitive
detergent [152], thermal sensitive liposomes [153], or reductive environment sensitive
disulfide cross-linker [154–156] have been explored to improve efficient self de-assembly of
the nanoparticles. Clever design with efficient de-assembly could also involve the release of
free membrane destabilizing molecules like cationic lipid, PEI or cationic peptides (for
example, R8) and thus helps endosome destabilization. Ideally, sufficient de-assembly and
endosome escape should occur at the same time. If successful, the required dose for siRNA
based therapy could be reduced dramatically.
6. Toxicity
6.1 siRNA-mediated immune stimulation
Toxicity is a major concern when a formulation is designed for human therapeutic purpose.
siRNA duplex (generally 19–21 base pairs) was originally thought to be immunologically
inert. It is sufficiently short to bypass the cell’s intrinsic anti-viral response that mediated by
the recognition of PKR (dsRNA-binding protein kinase) [157], the RNA helicase RIG-I
(retinoic acid-inducible gene-I) [158], and MDA-5 (melanoma differentiation-associated
protein-5) [159] in the cytoplasm. But recently, it has been shown that siRNA is capable of
induce the production of type I interferon (IFN-α and IFN-β) via activating of PKR [160–
162] or recognition by toll-like receptor 7, 8 and 9 (TLR 7/8/9) [163–165] especially with
the aid of delivery systems such as lipoplex [166]. This can further lead to the production of
other inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α),
and other pro-inflammatory chemokines [167] as well. Judge and MacLachlan et al. showed
that the recognition of siRNA by innate immune system is sequence specific [168]. Some
investigators misinterpreted their siRNA therapeutics results because they used a GFP
siRNA as a control which showed unusually low immuno-stimulatory activity. Kleinman et
al. also showed that non-targeted control siRNA could suppress angiogenesis as good as
siRNAs targeting vascular endothelial growth factor-A (VEGFA) or its receptor VEGFR1
via cell-surface TLR3 [169]. Non-specific angiogenesis inhibition and immune stimulation
are the toxicities which can confuse the data interpretation. It may be advantageous that
siRNA itself can induce immune response as a synergistic effect in cancer treatment [170] or
viral infection therapy. But it can be problematic for many other therapeutic purposes.
Strategies such as selective incorporation of 2’-O-methyl uridine or guanosine nucleosides
into one strand of siRNA duplex to overcome the immune response stimulated by siRNA
have been reported [171] and reviewed by Judge and MacLachlan [167].
6.2 Carrier-mediated side effect (focused on lipid-based systems)
Although lipid-based drug delivery systems are far less toxic than the viral systems, they are
not without overt toxicity. First, opsonins can attach to the charged surface of lipoplex as
previously mentioned and thus activate the complement pathway. Studies showed that
protecting the charged surface with PEG can prevent this side effect [172]. Second, in many
lipoplex delivery systems, pulmonary inflammation and increased TNF-α, IL-6, IL-12, and
interferon γ (INF-gamma;) have been observed [173–182]. This is mainly attributed to the
unmethylated CpG motifs in the plasmid DNA. To minimize the cytokine response,
strategies such as using methylated DNA [183] or non-bacterial amplification fragments
[184] and incorporating anti-inflammatory molecule into liposomes have been reported
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[178, 185, 186]. For the LPD formulation [61], calf-thymus DNA was used as a carrier for
siRNA. Calf-thymus DNA was selected because it contains fewer unmethylated CpG motifs
than the bacterial plasmid DNA and was thus less immuno-stimulatory. For human use it is
important to replace the DNA with other more acceptable carriers. Hyaluronic acid (HA) is a
highly negatively charged natural polymer. The new Liposome-protamine-HA (LPH)
nanoparticles significantly reduced the serum cytokine levels and still showed similar
characteristics and siRNA delivery capabilities comparable to the previous LPD formulation
[187]. Furthermore, recent data from this lab also showed that a particular cationic lipid, 1,2-
dioleoyl-3-trimethylammonium propane (DOTAP) not only played the role in transfection
but also stimulated dendritic cells and thus functioned as an adjuvant for vaccines [188,
189]. DOTAP at low concentration stimulated pERK which is an anti-apoptotic protein.
When DOTAP was a part of the LPD formulation for siRNA, it protected the tumor cells
from death (Chen et al. unpublished). The undesirable side effect of the formulation was
successfully eliminated by replacing DOTAP with another cationic lipid.
7. Examples of lipid-based siRNA delivery
Although there is still much to improve, lipid-based delivery system has been successfully
used in siRNA therapy. For example, Zimmermann et al. [104] developed a stable nucleic
acid lipid particle (SNALP) for delivering siRNA against apoB to the liver of monkeys.
Significant apoB protein, low-density lipoprotein, and cholesterol level reduction can be
achieved and lasted for up to 11 days. Halder et al. used their neutral liposomal formulation
to deliver anti-FAK siRNA to three different human ovarian tumor bearing nude mice. Four
days inhibition of FAK in tumor tissue and up to 72% mean tumor weight reduction was
observed [190]. Recently, they reported that anti IL-8 siRNA delivery could reduce the
micro-vessel density and the mean tumor weight by 32% and 52% in HeyA8 and SKOV3ip1
mouse models [191]. Since their lipid formulation was neutral, it is unclear how endosome
escape could take place. Morrissey et al. showed that siRNA against HBV encapsulated by
the polyethylene glycol (PEG) modified liposomes could reduce HBV titer in the mouse
liver [192]. Li et al. [61, 69, 193] developed a modified LPD (liposome-polycation-DNA)
formulation which was PEGylated and targeted with anisamide. The formulation was very
effective in delivering siRNA to sigma receptor expressing tumor cells. Specifically,
MDM2, c-myc, and VEGF siRNA combination was delivered to the pulmonary metastasis
model of melanoma. Significant tumor growth and inhibition was observed (Fig.4).
8. Summary
Lipid-based drug delivery system has been widely accepted in the clinic, especially in
chemotherapy, for more than two decades. Now, lipid-based delivery system also works
promisingly and safely in systemic siRNA delivery. Although the recent success is
encouraging, there still remains much room for improvement. If efficient tissue targeting
and endosome escape can be achieved at the same time, the effective dose required for
RNAi-based therapy may reduce significantly. This is important for two reasons. RNA is
still an expensive drug. Lower dose would mean lower cost of manufacture. At the same
time, the off-target side effect of siRNA [194, 195] would also be reduced. The challenge of
siRNA delivery will remain the focus of much research in drug delivery in the near future.
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Fig. 1. Endosome escape in lipoplex mediated siRNA delivery
A. Lipoplex containing siRNA (shown as orange lipid bilayer and red siRNA) with PEG and
targeting ligand on the tip (shown as blue circle) are taken up by target cell via receptor
mediated endocytosis.
B. The cationic lipid of the lipoplex forms ion pairs with the anionic endosomal lipid (PEG
molecules may leave the lipoplex spontaneously or under appropriate design) and can
further form the inverted hexagonal phase (HII). This leads to the fusion of the lipoplex with
endosomal membrane and release the siRNA into cytoplasm.
C. Lipoplex containing molecules having buffer capacity in endosomal pH range can trigger
proton sponge effect that causes the influx of Cl− and swelling of the endosome.
D. Free highly positive charged molecules (shown with orange colored cationic lipid and
purple colored PEI or oligo-arginine) can interact with anionic endosomal membrane and
destabilize it by excluding water.
E. Intact lipoplex may escape from the ruptured endosome and de-assemble in the cytoplasm
and release siRNA if the particle is not too large for the “holes” of the ruptured endosome.
F. Lipoplex may also de-assemble inside the endosome and directly release siRNA out of
the ruptured endosome.
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Proposed mechanism of endosome escape by lipoplex (figure taken from reference 128 with
permission). When lipoplex is endocytosed (step 1), the cationic lipids can interact with the
anionic membrane lipids in the early endosome by ion-pair formation (step 2). Thus, it
destabilizes the endosome membrane (step 3) with the formation of the inverted hexagonal
phase (HII), indicated by the red circle, as proposed by Cullis et al [131]. At the end, it
causes the release of cargos (showed as plasmid DNA) to the cytoplasm (step 4).
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Difference between oligo-arginine and oligo-lysine in ion-pairing with negatively charged
group. Oligo-arginine has delocalized positively charged guanidinium (B) groups that can
interact strongly with delocalized anion phosphate groups. Note that H-bondings are also
involved in the interaction. On the other hand, the positive charged ammonium groups (A)
of oligo-lysine are not delocalized. Figure is reproduced from reference [137] with
permission.
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LPD nanoparticles (NP) deliver siRNA for metastatic tumor growth inhibition. Mice were
i.v. injected with lung-homing B16F10 melanoma cells. After 10 days, mice were
intravenously injected twice with siRNA (0.45 mg/kg, MDM2/c-myc/VEGF = 1:1:1, weight
ratio). Six days later, the mice were sacrificed for examination of tumor growth. The lungs
of individual mice were photographed. Only the mice injected with the targeted NP
containing therapeutic siRNA showed significant reduction in tumor load. Figure is
reproduced from reference [69] with permission.
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